Zentalis picks 400 mg azenosertib dose for pivotal ovarian cancer trials

Reuters04-09

Zentalis picks 400 mg azenosertib dose for pivotal ovarian cancer trials

Zentalis selected 400 mg once-daily on a 5-days-on, 2-days-off schedule as pivotal monotherapy dose for investigational WEE1 inhibitor azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer.
Decision follows a prespecified interim analysis from DENALI Part 2a, with results already reviewed internally rather than separately reported.
Interim findings supported a more favorable benefit-risk profile at selected dose versus lower dose, driven by stronger tumor response with similar safety.
Selected regimen will be used in ongoing potentially pivotal DENALI Phase 2 trial plus confirmatory ASPENOVA Phase 3 trial.
Zentalis expects DENALI Part 2 topline results by year-end 2026, with enrollment expansion planned to start in Q2 2026 to reflect shifting treatment patterns.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604090800PRIMZONEFULLFEED9686835) on April 09, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626184921?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626184921","market":"fut","top_or_hot":-1,"title":"Zentalis picks 400 mg azenosertib dose for pivotal ovarian cancer trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zentalis picks 400 mg azenosertib dose for pivotal ovarian cancer trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Zentalis selected 400 mg once-daily on a 5-days-on, 2-days-off schedule as pivotal monotherapy dose for investigational WEE1 inhibitor azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer.\n        </li>\n<li>\n          Decision follows a prespecified interim analysis from DENALI Part 2a, with results already reviewed internally rather than separately reported.\n        </li>\n<li>\n          Interim findings supported a more favorable benefit-risk profile at selected dose versus lower dose, driven by stronger tumor response with similar safety.\n        </li>\n<li>\n          Selected regimen will be used in ongoing potentially pivotal DENALI Phase 2 trial plus confirmatory ASPENOVA Phase 3 trial.\n        </li>\n<li>\n          Zentalis expects DENALI Part 2 topline results by year-end 2026, with enrollment expansion planned to start in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026 to reflect shifting treatment patterns.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604090800PRIMZONEFULLFEED9686835) on April 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zentalis picks 400 mg azenosertib dose for pivotal ovarian cancer trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZentalis picks 400 mg azenosertib dose for pivotal ovarian cancer trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-09 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zentalis picks 400 mg azenosertib dose for pivotal ovarian cancer trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Zentalis selected 400 mg once-daily on a 5-days-on, 2-days-off schedule as pivotal monotherapy dose for investigational WEE1 inhibitor azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer.\n        </li>\n<li>\n          Decision follows a prespecified interim analysis from DENALI Part 2a, with results already reviewed internally rather than separately reported.\n        </li>\n<li>\n          Interim findings supported a more favorable benefit-risk profile at selected dose versus lower dose, driven by stronger tumor response with similar safety.\n        </li>\n<li>\n          Selected regimen will be used in ongoing potentially pivotal DENALI Phase 2 trial plus confirmatory ASPENOVA Phase 3 trial.\n        </li>\n<li>\n          Zentalis expects DENALI Part 2 topline results by year-end 2026, with enrollment expansion planned to start in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026 to reflect shifting treatment patterns.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604090800PRIMZONEFULLFEED9686835) on April 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL2PYgJ4:1","article_id":"2626184921","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626184921","pubTimestamp":1775736545,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zentalis selected 400 mg once-daily on a 5-days-on, 2-days-off schedule as pivotal monotherapy dose for investigational WEE1 inhibitor azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer.Decision follows a prespecified interim analysis from DENALI Part 2a, with results already reviewed internally rather than separately reported.Interim findings supported a more favorable benefit-risk profile at selected dose versus lower dose, driven by stronger tumor response with similar safety.Selected regimen will be used in ongoing potentially pivotal DENALI Phase 2 trial plus confirmatory ASPENOVA Phase 3 trial.Zentalis expects DENALI Part 2 topline results by year-end 2026, with enrollment expansion planned to start in Q2 2026 to reflect shifting treatment patterns.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4139":"生物科技","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","ZNTL":"Zentalis Pharmaceuticals, LLC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Zentalis选择400 mg azenosertib剂量用于关键卵巢癌试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZNTL":0.9,"NDAQ":0.9},"content_text":"Zentalis picks 400 mg azenosertib dose for pivotal ovarian cancer trials\n    \n\n\n          Zentalis selected 400 mg once-daily on a 5-days-on, 2-days-off schedule as pivotal monotherapy dose for investigational WEE1 inhibitor azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer.\n        \n\n          Decision follows a prespecified interim analysis from DENALI Part 2a, with results already reviewed internally rather than separately reported.\n        \n\n          Interim findings supported a more favorable benefit-risk profile at selected dose versus lower dose, driven by stronger tumor response with similar safety.\n        \n\n          Selected regimen will be used in ongoing potentially pivotal DENALI Phase 2 trial plus confirmatory ASPENOVA Phase 3 trial.\n        \n\n          Zentalis expects DENALI Part 2 topline results by year-end 2026, with enrollment expansion planned to start in Q2 2026 to reflect shifting treatment patterns.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604090800PRIMZONEFULLFEED9686835) on April 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626184921","isCrawlerRequest":true}